On April 28, 2022 BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs, reported three poster presentations relating to lead asset plinabulin at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting being held June 3-7, 2022, in Chicago, Illinois and virtually (Press release, BeyondSpring Pharmaceuticals, APR 28, 2022, View Source;utm_medium=rss&utm_campaign=beyondspring-announces-three-poster-presentations-at-the-american-society-of-clinical-oncology-asco-annual-meeting [SID1234613099]). One of the posters includes an analysis of the use of granulocyte colony-stimulating factor (G-CSF) to prevent febrile neutropenia (FN) in breast cancer patients early and late in the chemotherapy cycle. The other two posters contain new data from the DUBLIN-3 Phase 3 non-small cell lung cancer (NSCLC) treatment program. One focuses on a quality of life (QoL) analysis that compares patients who received plinabulin with docetaxel versus those who didn’t. The other includes the results of a subgroup analysis in non-squamous NSCLC patients.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Additional presentation details can be found below:
Title: Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN–risk chemotherapy (chemo)
Abstract #: 599
Poster Session: Breast Cancer—Local/Regional/Adjuvant
Date/Time: June 6, 2022, 9 AM EDT
Presenter: Douglas W. Blayney, M.D., FASCO, Stanford University
Title: DUBLIN-3 results on quality of life (QoL) in second/third-line EGFR-wild type NSCLC patients (pts) receiving docetaxel (Doc) with or without plinabulin (Plin) using the validated EORTC QLQ C30 and QLQ LC13 questionnaires
Abstract #: 9091
Session: Lung Cancer—Non-Small Cell Metastatic
Date/Time: June 6, 2022, 9 AM EDT
Presenter: Trevor Feinstein, M.D., Piedmont Cancer Institute
Title: Subgroup analysis in patients (pts) with non-squamous (N-Sq), EGFR-wild type (wt), second/third-line NSCLC from the global phase (Ph) 3 trial DUBLIN-3 (BPI-2358-103) with the plinabulin/docetaxel (Plin/Doc) combination versus Doc alone
Abstract #: 9090
Session: Lung Cancer—Non-Small Cell Metastatic
Date/Time: June 6, 2022, 9 AM EDT
Presenter: Baohui Han, M.D., Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University